Pharma Focus America
ThermoFisher Scientific - Go beyond the catalog

Lilly Plans to invest US $450 million at a US Manufacturing Site


Eli Lilly plans to invest US $450 million in a facility in the Research Triangle Park area of the United States, to expand its manufacturing capabilities.


To meet the growing demand for Lilly's incretin-based diabetes treatments, the expansion includes more parenteral filling, device assembly, and packaging capacity.

The FDA inspections at Research Triangle Park are presently being prepared for, and initial manufacturing is anticipated to begin this year.

This expansion is crucial for ensuring the availability of current Lilly medications and for setting the pharmaceuticals' worldwide distribution.

During this phase of the project, it is anticipated that at least 100 new jobs will be generated, mostly for manufacturing staff who will use cutting-edge technology to produce incretin treatments and medical devices.

The production site's operations are expected to start in 2027.


NameEli Lilly
BudgetUS $450 million
Sartorius Lab Balance CleaningFestival of Biologics San Diego 2024Equinix accelerated medical research...World Vaccine Congress Europe 2024World Orphan Drug Congress 2024World Vaccine Congress Washington 2024Future Labs Live USA 2024Interphex 2024Pharma USA 2024Healthcare CNO SummitHealthcare CMO Summit